Better Outcomes for Patients will Provide Better Business Outcomes

It will not have escaped your attention that ‘patient centricity’ has become something of a catchphrase in the last couple of years: mission statements and company announcements are full of it. Cynics have yet to be convinced, but some believers in pharma are working to win them over. John McCarthy, VP Global Commercial Excellence at AstraZeneca, thinks he has the tools to make the idea something more concrete. The international team he leads has a daunting remit: to build and deliver capabilities to drive commercial success, transform the healthcare experience and improve the lives of millions of patients. Measuring the journey In short, he is leading the charge to make AstraZeneca a patient-centric organization. To know you are achieving this broad and ambitious set of aims requires a laser-like focus on outcomes, and McCarthy believes it is vital to build in measurement from the start. However, there may be a limit to the usefulness of traditional KPIs in this environment. “There are many ways to measure along this journey,” McCarthy says. “We’re probably not measuring patient centricity at a corporate level just yet, but if you’re doing journey mapping and understand the problems, that is probably a measure. KPIs too often bring you back to the business outcome only.” Instead, he suggests, you need to look for evidence that you are solving a problem for patients. The $64 million question which follows on from this – an...
Source: EyeForPharma - Category: Pharmaceuticals Authors: Source Type: news

Related Links:

Authors: Kim SE, Lee SJ, Cha JY, Yi SW, Kim TS, Cho IL, Kwak JY, Oh KH Abstract Colon cancer is very rarely accompanied by tumor thrombosis of the superior mesenteric vein (SMV). A 46-year-old patient had been diagnosed with SMV tumor thrombosis related to colon cancer without hepatic metastasis and underwent right hemicolectomy with SMV tumor thrombectomy. Tumor thrombosis was pathologically confirmed as metastatic colon cancer. There has been no recurrence for 12 months with 12 cycles of adjuvant-chemotherapy. PMID: 30992420 [PubMed - as supplied by publisher]
Source: Clinical Endoscopy - Category: Gastroenterology Tags: Clin Endosc Source Type: research
Publication date: Available online 17 April 2019Source: The Journal of Molecular DiagnosticsAuthor(s): Emily B. Hollister, Numan Oezguen, Bruno P. Chumpitazi, Ruth Ann Luna, Erica M. Weidler, Michelle Rubio-Gonzales, Mahmoud Dahdouli, Julia L. Cope, Toni-Ann Mistretta, Sabeen Raza, Ginger A. Metcalf, Donna M. Muzny, Richard A. Gibbs, Joseph F. Petrosino, Margaret Heitkemper, Tor C. Savidge, Robert J. Shulman, James VersalovicAccurate diagnosis and stratification of children with irritable bowel syndrome (IBS) remain challenging. Given the central role of recurrent abdominal pain in IBS, we evaluated the relationships of pe...
Source: The Journal of Molecular Diagnostics - Category: Pathology Source Type: research
Publication date: Available online 18 April 2019Source: Pathology - Research and PracticeAuthor(s): Xiao-Jie Chen, Ya-Qin Tan, Na Zhang, Ming-Jing He, Gang ZhouAbstractObjectiveIn recent years, monoclonal antibodies targeting programmed cell death-ligand 1 (PD-L1) have become a promising cancer immunotherapy. However, the role of PD-L1 in oral squamous cell carcinoma (OSCC) and oral potentially malignant disorders (OPMDs), including oral leukoplakia (OLK), remains controversial. The aim of the present study was to investigate the expression level of PD-L1 in OSCC and OPMDs, and examine its relationship with CD8 expression ...
Source: Pathology Research and Practice - Category: Pathology Source Type: research
In conclusion, our findings indicate that targeting miR-142-5p may provide a novel strategy for the treatment of pancreatic cancer.
Source: Pathology Research and Practice - Category: Pathology Source Type: research
Conclusions: Our study demonstrated that TRIP13 might be a tumor promoting factor in ESCC and a promising prognostic indicator for ESCC patient.
Source: Pathology Research and Practice - Category: Pathology Source Type: research
In conclusion, B7-H3 could be a target of bone cancers.
Source: Pathology Research and Practice - Category: Pathology Source Type: research
ConclusionCircRNAs have high sensitivity and specificity in the diagnosis of gastric cancer, and it may become an auxiliary diagnostic biomarker of gastric cancer.
Source: Pathology Research and Practice - Category: Pathology Source Type: research
In this study we demonstrate the use of clustered regularly interspaced short palindromic repeats (CRISPR)-based epigenome editing to alter cell response to inflammatory environments by repressing inflammatory cytokine cell receptors, specifically TNFR1 and IL1R1. This has applications for many inflammatory-driven diseases. It could be applied for arthritis or to therapeutic cells that are being delivered to inflammatory environments that need to be protected from inflammation." In chronic back pain, for example, slipped or herniated discs are a result of damaged tissue when inflammation causes cells to create ...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
Editor’s Note: This essay contains excerpts from Extreme Measures: Finding a Better Path to the End of Life, coming February 21st, 2017 from Penguin-Random House. A few years ago, while at a family get-together, I sat across from a retired hospice social worker named Terry. I am a physician whose practice alternates between attending on the wards of an inner-city intensive care unit and serving as a consultant on the hospital’s palliative care team. I didn’t set out to practice this uncommon combination of medical specialties. I started out totally dedicated to using the miraculous technologies in my crit...
Source: Health Affairs Blog - Category: Health Management Authors: Tags: End of Life & Serious Illness Health Professionals Hospitals 30-day mortality statistic advance directive Palliative Care Source Type: blogs
I am in a perpetual abusive relationship with hypochondria; I desperately want to get away from it, but somehow it controls my brain. I've had hypochondriac tendencies (more officially known as "illness anxiety disorder") for as long as I can remember. I'm not sure who or what to blame and the source of the disorder is irrelevant; it's the cure I'm after. Hypothesis theories for my hypochondria: Throughout my childhood, my mother perpetually complained of a bad heart and threatened to faint, falling back on her stash of smelling salts in her purse. The best birthday present I ever got was the Merck Medical Ma...
Source: Healthy Living - The Huffington Post - Category: Consumer Health News Source Type: news
More News: AstraZeneca | Back Pain | Cancer | Cancer & Oncology | Cardiology | Education | Environmental Health | Health | Heart | Heart Attack | Heart Transplant | Hospitals | Learning | Lung Cancer | Lung Transplant | Medical Devices | Pain | Pharmaceuticals | Science | Transplant Surgery | Transplants | Universities & Medical Training